Mus musculus
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA98381 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Alox5 Knockout Signature in Mouse White Adipose Tissue
| PRJNA98379 | ENA
Project description:Zfp90 Transgenic Signature in Mouse White Adipose Tissue
| PRJNA98385 | ENA
Project description:Gene expression from mouse white, brown, and perivascular adipose tissue
| PRJNA139249 | ENA
Project description:Purpose: To investigate the involvement of mTORC1 as a mediator of the actions of the PPARγ ligand rosiglitazone in subcutaneous inguinal white adipose tissue transcriptome; Methods: Mice bearing regulatory associated protein of mTOR (Raptor) deletion and therefore mTORC1 deficiency exclusively in adipocytes (adiponectin Cre recombinase) and littermate controls were fed a high-fat diet supplemented or not with the PPARγ agonist rosiglitazone (30 mg/kg/day) for 8 weeks and evaluated for inguinal white adipose tissue transcriptome (Rnaseq); Results: 3,2425 genes had their correspondent mRNA levels altered by either adipocyte Raptor deficiency or rosiglitazone administration or their combination. Among those, 408 genes modulated by rosiglitazone required mTORC1. Conclusion: PPARγ and mTORC1 are essential partners in the regulation of a cluster of genes in inguinal white adipose tissue.
2022-02-01 | GSE166988 | GEO
Project description:Pparg<ldi/+> white Adipose Tissue expression differentials
| PRJNA105235 | ENA
Project description:Brown versus white tissue adipose selective genes
| PRJNA100865 | ENA
Project description:The purpose of this experiment was to determine the murine white adipose expression traits that were changed in response to treatment with Rosiglitazone. Keywords: drug treatment response signature
2007-02-17 | GSE7027 | GEO
Project description:White adipose tissue regulates metabolism; the importance of this control is highlighted by the ongoing pandemic of obesity and associated complications such as diabetes, atherosclerosis, and cancer. White adipose tissue maintenance is a dynamic process, very little is known about how pharmacologic stimuli affect such plasticity. Combining in vivo lineage marking and BrdU labeling strategies, we found that rosiglitazone, a member of the thiazolidinedione class of glucose-lowering medicines, markedly increases the evolution of adipose progenitors into adipocytes. Notably, chronic rosiglitazone administration disrupts the adipogenic and self-renewal capacities of the stem cell compartment and alters its molecular characteristics. These data unravel unknown aspects of adipose dynamics and provide a basis to manipulate the adipose lineage for therapeutic ends. The goal of this gene expression array was to identify changes in molecular expression in adipose progenitors isolated from mice that underwent two-month rosiglitazone treatment.
2012-01-18 | GSE30116 | GEO